Drug profile · INN
mecasermin recombinant
INCRELEX
mecasermin recombinant (INCRELEX) is a insulin-like growth factor i receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — mecasermin recombinant
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
mecasermin recombinant (INCRELEX) is a insulin-like growth factor i receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin-like growth factor I receptor agonist
Primary target: Insulin-like growth factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is mecasermin recombinant?
mecasermin recombinant (INCRELEX) is a insulin-like growth factor i receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for mecasermin recombinant?
INCRELEX is a marketed brand name for mecasermin recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mecasermin recombinant?
mecasermin recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.